Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)

Soon-Ae KIM; Woo-Ho SHIM; Eun-Hae LEE; Young-Mi LEE; Sun-Hee BEOM; Eun-Sook KIM; Jeong-Seon YOO; Ji-Sun NAM; Min-Ho CHO; Jong-Suk PARK; Chul-Woo AHN; Kyung-Rae KIM.
Diabetes & Metabolism Journal ; : 300-301, 2011.
Artículo en Inglés | WPRIM | ID: wpr-191960

Documentos relacionados

  1. Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes.
  2. Sex-Related Differences in Sitagliptin Treatment in Type 2 Diabetes: Results from the PROLOGUE Trial.
  3. Reply.
  4. Understanding the Adsorption and Desorption of Sitagliptin Phosphate Monohydrate on SS2343, Glass, and PTFE Using QCM-D and Raman Spectroscopy.
  5. Identification of sitagliptin binding proteins by affinity purification mass spectrometry.
  6. [Incretin enhancer: sitagliptin].
  7. Development of extended-release metformin core tablet and synergistic coating of sitagliptin for the treatment of type-II diabetes mellitus - A comparative drug release evaluation with reference product.
  8. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study.
  9. [Cardiovascular safety of sitagliptin added to metformin in real world patients with type 2 diabetes].
  10. Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.